Detalhe da pesquisa
1.
Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma.
Oncologist
; 23(9): 1004-e102, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29769385